Toripalimab plus chemotherapy for advanced small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of an immunotherapy drug (toripalimab) and chemotherapy for people with advanced small cell lung cancer that has progressed after previous treatments. It aims to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have extensive stage small cell lung cancer, which means it has spread beyond one lung.
- You have not received immunotherapy before, OR you received it and it worked for more than 3 months and you stopped it more than 3 months ago.
- You have never taken the targeted therapy drug anlotinib.
- You are physically able to care for yourself (ECOG score 0-2) and your major organs are working normally.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at how well the drug toripalimab works in people with extensive-stage small cell lung cancer when it's the first treatment they receive. It's a real-world study, meaning it observes what happens in everyday medical care.
This trial tests whether giving an immunotherapy drug called toripalimab together with chemotherapy after lung cancer surgery can help prevent small cell lung cancer from coming back. It is for people who had surgery to remove lung cancer and were found to have small cell lung cancer in the removed tissue.
This trial tests whether adding two immunotherapy drugs (toripalimab and JS004) to standard chemotherapy before surgery can help shrink limited-stage small cell lung cancer. The goal is to find better ways to treat this cancer before surgery.
This study tests a new drug (BL0020) combined with an immunotherapy drug (toripalimab) for people with extensive-stage small cell lung cancer that has returned after initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests whether adding toripalimab (an immunotherapy) or toripalimab plus another immunotherapy (tifcemalimab) after standard chemoradiation can help prevent small cell lung cancer from coming back. It is for people with limited-stage disease who have finished initial treatment without the cancer growing.
This trial tests a new combination of two immunotherapy drugs plus chemotherapy, followed by radiation to the chest, for people with extensive-stage small cell lung cancer who have not been treated yet. The goal is to see if this approach can shrink the cancer and help people live longer.
Hear when a new SCLC, Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.